Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.59 |
| ▸ | KIF11 | P52732 | 8/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
| ▸ | ULK1 | O75385 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16208480 | 0.81 | KIF11 (0.72) | MAPK14MAPK13MAPK12MAPK11KIF11 | |
| SCHEMBL16208505 | 0.81 | KIF11 (0.67) | MAPK14KIF11ULK1 | |
| SCHEMBL20773171 | 0.80 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL30800742 | 0.80 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL25875012 | 0.80 | KIF11 (0.65) | KIF11CRBNULK1 | |
| SCHEMBL16208502 | 0.80 | KIF11 (0.67) | KIF11CRBNULK1TNIK | |
| SCHEMBL22159529 | 0.78 | CRBN (0.77) | MAPK14KIF11CRBNULK1NPC1 | |
| SCHEMBL20773056 | 0.78 | CRBN (0.60) | MAPK14KIF11CRBNULK1NPC1 | |
| SCHEMBL20774011 | 0.78 | CRBN (0.60) | MAPK14KIF11CRBNULK1 | |
| SCHEMBL30800736 | 0.78 | CRBN (0.60) | MAPK14KIF11CRBNULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192643-A1 | DIHYDROQUINOLINONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192643-A1 | DIHYDROQUINOLINONES FOR MEDICAL TREATMENT | CRBN, RBX1, ADRM1 | MAPK14 2954/4885MAPK13 3288/4885MAPK12 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.